BioSpace News Archive

Innovation Pharmaceuticals, a clinical stage pharmaceutical company, is pleased to inform shareholders the Company received notification from the Food and Drug Administration that a waiver has been granted eliminating the need to study Brilacidin, for the prevention of Severe Oral Mucositis in Head and Neck Cancer patients receiving chemoradiation, in pediatric populations.

Corporate culture is interesting because it affects almost every aspect of a business.

Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced the closing of its previously announced offering.

BioSyent Inc. is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive License and Supply Agreement with AFT Pharmaceuticals for a portfolio of new pain management products for the Canadian market.

Resverlogix Corp. announces a warrant exercise incentive program designed to encourage the early exercise of 15,593,428 warrants to purchase common shares of the Company.

Alzheimer’s Research UK welcomes the Conservatives’ pledge to double investment in dementia research as a ‘step in the right direction’.

ERYTECH Pharma announced that the full results from its Phase 2b trial evaluating eryaspase in metastatic pancreatic cancer are now published online in the European Journal of Cancer.

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced initiation of the NEURO-TTRansform Phase 3 clinical trial for AKCEA-TTR-LRx in patients with polyneuropathy caused by hereditary TTR amyloidosis, or hATTR amyloidosis.

Filing submission includes 12-month data from pivotal FIREFISH and SUNFISH trials in a broad population of people living with Types 1, 2 or 3 SMA

PTC Therapeutics, Inc. announced that the United States Food and Drug Administration has granted priority review for the New Drug Application for risdiplam for the treatment of spinal muscular atrophy.